Article Text

Download PDFPDF
Examining the added value of microperimetry and low luminance deficit for predicting progression in age-related macular degeneration
  1. Zhichao Wu1,2,
  2. Chi D Luu1,2,
  3. Lauren AB Hodgson1,
  4. Emily Caruso1,
  5. Fred K Chen3,
  6. Usha Chakravarthy4,
  7. Jennifer J Arnold5,
  8. Wilson J Heriot6,
  9. Jim Runciman7,
  10. Robyn H Guymer1,2
  1. 1 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
  2. 2 Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Australia
  3. 3 Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Perth, Australia
  4. 4 Belfast Health and Social Care Trust, Belfast, Northern Ireland
  5. 5 Marsden Eye Research, Sydney, Australia
  6. 6 Retinology Institute Victoria, Melbourne, Australia
  7. 7 Adelaide Eye and Retina Centre, Adelaide, Australia
  1. Correspondence to Zhichao Wu, Centre for Eye Research Australia, Level 7, 32 Gisborne Street, East Melbourne, Australia; wu.z{at}unimelb.edu.au

Abstract

Purpose To examine the added predictive value of microperimetric sensitivity and low luminance deficit (LLD; difference between photopic and low luminance visual acuity (VA)) to information from colour fundus photography (CFP) for progression to late age-related macular degeneration (AMD) in individuals with bilateral large drusen.

Methods 140 participants with bilateral large drusen underwent baseline microperimetry testing, VA measurements and CFP. They were then reviewed at 6-monthly intervals to 36 months, to determine late AMD progression. Microperimetry pointwise sensitivity SD (PSD), LLD and the presence of pigmentary abnormalities on CFPs were determined. Predictive models based on these parameters were developed and examined.

Results Baseline microperimetry PSD and presence of pigmentary abnormalities were both significantly associated with time to develop late AMD (p≤0.004), but LLD was not (p=0.471). The area under the receiver operating characteristic curve (AUC) for discriminating between eyes that progressed to late AMD based on models using microperimetry PSD (AUC=0.68) and LLD (AUC=0.58) alone was significantly lower than that based on CFP grading for the presence of pigmentary abnormalities (AUC=0.80; both p<0.005). Addition of microperimetry and/or LLD information to a model that included CFP grading did not result in any improvement in its predictive performance (AUC=0.80 for all; all p≥0.66).

Conclusions While microperimetry, but not LLD, was significantly and independently associated with AMD progression at the population level, this study observed that both measures were suboptimal at predicting progression at the individual level when compared to conventional CFP grading and their addition to the latter did not improve predictive performance.

  • Retina
  • Psychophysics
  • Diagnostic tests/Investigation
  • Clinical Trial
  • Macula
  • Electrophysiology
  • Prosthesis
  • Imaging
  • Public health
  • Treatment Surgery
  • Vitreous
  • Stem Cells
  • Neovascularisation
  • Treatment Medical
  • Angiogenesis
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This study was supported by National Health & Medical Research Council of Australia (project grant no.: APP1027624 (RHG and CDL), and fellowship grant no.: GNT1103013 (RHG), APP1104985 (ZW), APP1054712 (FKC) and APP1142962 (FKC)) and BUPA Health Foundation (Australia) (RHG and CDL). CERA receives operational infrastructure support from the Victorian Government. The web-based Research Electronic Data Capture (REDCap) application and open-source platform OpenClinica allowed secure electronic data capture. The study is sponsored by the Centre for Eye Research Australia (CERA), an independent medical research institute and a not-for-profit company.

  • Competing interests RHG reports personal fees from Bayer, Novartis, Roche Genentech and Apellis outside the submitted work and research grant from Bayer outside the submitted work. FKC reports personal fees from Bayer, Novartis, Allergan, Heidelberg Engineering, Alcon and Pfizer outside the submitted work and aresearch grant from Novartis and Bayer outside the submitted work. UC reports personal fees from Bayer, Novartis, Roche outside the submitted work and aresearch grant from Bayer, Novartis, Roche outside the submitted work. JJA reports personal fees from Allergan, Bayer and Novartis. WJH reports personal fees from Alcon, Bayer and Novartis outside the submitted work. JR reports personal fees from Ellex Medical Lasers Ltd outside the submitted work. ZW, CDL, LABH and EC report nothing to declare.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.